… Epidermal growth factor receptor inhibitors are used to treat … of therapy serves as a model
for other targeted therapies in … Evaluation of EGFR-activating mutations is currently used to …

… would derive the most benefit from treatment with … EGFR inhibition in normal skin and in
tumor tissues. In addition, it is possible that the downstream effects of inhibiting EGFR in skin …

… failed a previous treatment with irinotecan, obtained partial responses … EGFR inhibitors the
levels of expression of the other three EGFR-related growth factor receptors and of the EGFR …

… 10) is the fourth-generation EGFR inhibitor obtained by high-throughput screening (HTS)
strategy from a library of 2.5 million compounds at 1 µM ATP concentration. EAI001 57 is a …

… receptor tyrosine-kinase inhibitors. In this review, results of most recent clinical with EGFR
inhibitors … -EGF, EMD 72000), and tyrosine-kinase inhibitors, such as ZD1839 (Gefitinib, Iressa)…

… EGFR expression are refractory to EGFR inhibitor treatment, suggesting that mere expression
of EGFR is not a robust predictor of response to therapy. … , mainly quinazoline-derived, low …

… ZD1839, a po active, selective quinazoline derivative has … This mini-review describes the
EGFR inhibitors in clinical … a 6-thiazolylquinazoline derivative that selectively inhibits with …

… -positive advanced CRC patients, who had failed a previous treatment with irinotecan,
obtained partial responses in 22.5% of patients with a median duration of response of 6 months […

Treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) … -TKIs
(eg, afatinib and dacomitinib) are effective for the treatment of EGFR-mutated NSCLC, …

… inhibitors are small molecules derived from … epidermal growth factor receptor inhibitors in
the treatment of metastatic colorectal cancer, and to define the contexts in which EGFR inhibitor …